|
COPYRIGHT 2006 PR Newswire Association LLC
RADFORD, Va., June 30 /PRNewswire/ -- New River Pharmaceuticals Inc. announced today that an investigational new drug application (IND) has been submitted to the U.S. Food and Drug Administration for NRP409.
On June 29, New River submitted an IND on NRP409, the company's Carrierwave(TM) triiodothyronine (T3) hormone, as a treatment for patients with primary hypothyroidism. The company hopes that by reducing the variability of the hormone's availability, while reducing the safety risk associated with other T3 based therapies, NRP409 will mark the first significant improvement in thyroid hormone replacement therapy in approximately half a century.
New River expects to begin enrollment in clinical studies of NRP409 by 3Q06. The company anticipates that NRP409 should warrant a relatively abbreviated development pathway...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
